Jump to content

Nealbarbital

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Buidhe (talk | contribs) at 07:41, 7 December 2023 (Removing from Category:GABAA receptor positive allosteric modulators in subcat using Cat-a-lot). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Nealbarbital
Clinical data
Other namesNealbarbital, Censedal
ATC code
  • none
Identifiers
  • 5-allyl-5-(1,1-dimethylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.008.386 Edit this at Wikidata
Chemical and physical data
FormulaC12H18N2O3
Molar mass238.287 g·mol−1
3D model (JSmol)
  • O=C1NC(=O)NC(=O)C1(CC(C)(C)C)C\C=C
  • InChI=1S/C12H18N2O3/c1-5-6-12(7-11(2,3)4)8(15)13-10(17)14-9(12)16/h5H,1,6-7H2,2-4H3,(H2,13,14,15,16,17) checkY
  • Key:YHKPTICJRUESOY-UHFFFAOYSA-N checkY
  (verify)

Nealbarbital (Censedal) is a barbiturate derivative developed by Aktiebolaget Pharmacia in the 1950s.[1] It has sedative and hypnotic effects, and was used for the treatment of insomnia.

References

[edit]
  1. ^ US Patent 2899435